Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating trilaciclib in combination with chemotherapy followed by avelumab for advanced/metastatic urothelial carcinoma/bladder cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-08-17